Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease

被引：22

作者：

Toss, H ^{[1
]}

Wallentin, L

Siegbahn, A

机构：

[1] Univ Uppsala Hosp, Dept Cardiol, S-75185 Uppsala, Sweden

[2] Univ Uppsala Hosp, Lab Coagulat Res, Dept Clin Lab Sci, S-75185 Uppsala, Sweden

来源：

AMERICAN HEART JOURNAL | 1999年 / 137卷 / 01期

关键词：

D O I：

10.1016/S0002-8703(99)70461-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background In the FRISC trial, dalteparin 120 IU/kg body weight twice daily for unstable coronary artery disease was safe and reduced the risk of new coronary events. This risk reduction was maintained during the following extended treatment with a fixed dose of 7500 IU dalteparin once daily. Methods and results Minor bleeding was more frequent in women compared with men: relative risk (CI) 2.88 (1.78 to 4.67) during the weight-adjusted and 2.36 (1.37 to 2.63) during the fixed dose treatment. The anti-Xa activity determined in samples (n = 175) obtained during the acute phase treatment was higher in women compared with men (P < .001) and in nonsmokers compared with smokers (< .001) in multiple regression analysis. Also, during the fixed-dose treatment (n = 131) an independent relation between anti-Xa activity and sex (P < .001), but not smoking habits, persisted. Conclusion To improve future low-molecular-weight heparin dose regimens for the treatment of acute coronary syndromes, it might be important to consider the influence of sex and smoking habits.

引用

页码：72 / 78

页数：7

共 27 条

[1]

ALHENCGELAS M, 1994, THROMB HAEMOSTASIS, V71, P698

[2] THE DISAPPEARANCE OF A LOW-MOLECULAR-WEIGHT HEPARIN FRACTION (CY-216) DIFFERS FROM STANDARD HEPARIN IN RABBITS [J].

BONEU, B ;

BUCHANAN, MR ;

CARANOBE, C ;

GABAIG, AM ;

DUPOUY, D ;

SIE, P ;

HIRSH, J .

THROMBOSIS RESEARCH, 1987, 46 (06) :845-853

[3] COMPARISON OF LOW-MOLECULAR WEIGHT HEPARIN VS UNFRACTIONATED HEPARIN IN GYNECOLOGICAL SURGERY [J].

BORSTAD, E ;

URDAL, K ;

HANDELAND, G ;

ABILDGAARD, U .

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1988, 67 (02) :99-103

[4] LOW-MOLECULAR-WEIGHT HEPARIN (KABI-2165, FRAGMIN) - PHARMACOKINETICS AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION IN HUMAN VOLUNTEERS [J].

BRATT, G ;

TORNEBOHM, E ;

WIDLUND, L ;

LOCKNER, D .

THROMBOSIS RESEARCH, 1986, 42 (05) :613-620

[5]

Braunwald E, 1997, J AM COLL CARDIOL, V29, P1474

[6] HEPARIN KINETICS - VARIABLES RELATED TO DISPOSITION AND DOSAGE [J].

CIPOLLE, RJ ;

SEIFERT, RD ;

NEILAN, BA ;

ZASKE, DE ;

HAUS, E .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (03) :387-393

[7] A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [J].

Cohen, M ;

Demers, C ;

Gurfinkel, EP ;

Turpie, AGG ;

Fromell, GJ ;

Goodman, S ;

Langer, A ;

Califf, RM ;

Fox, KAA ;

Premmereur, J ;

Bigonzi, F .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) :447-452

[8] Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate [J].

Cosmi, B ;

Fredenburgh, JC ;

Rischke, J ;

Hirsh, J ;

Young, E ;

Weitz, JI .

CIRCULATION, 1997, 95 (01) :118-124

[9] THE ANTITHROMBOTIC ACTIVITY AND PHARMACOKINETICS OF ENOXAPARINE, A LOW-MOLECULAR WEIGHT HEPARIN, IN HUMANS GIVEN SINGLE SUBCUTANEOUS DOSES OF 20 TO 80 MG [J].

FRYDMAN, AM ;

BARA, L ;

LEROUX, Y ;

WOLER, M ;

CHAULIAC, F ;

SAMAMA, MM .

JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (07) :609-618

[10] Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after Streptokinase (and heparin) in acute myocardial infarction [J].

Glick, A ;

Kornowski, R ;

Michowich, Y ;

Koifman, B ;

Roth, A ;

Laniado, S ;

Keren, G .

AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (14) :1145-1148

← 1 2 3 →